Paradigm Biocapital Advisors LP

Position in ERAS — Erasca, Inc.

CIK 1855655 NEW YORK, NY

Position in ERAS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$168,153,918

+$115,482,085 QoQ

Shares Held

10,392,702

-26.6% QoQ

Ownership

3.34%

of shares outstanding

% of Portfolio

3.44%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2024

8 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Paradigm Biocapital Advisors LP holds $4,894,261,596 across 35 Biotechnology names. ERAS ranks #10 (3.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ACLX	Arcellx, Inc.	5,774,016	$662,972,517
2	RVMD	Revolution Medicines, Inc.	6,655,703	$647,267,116
3	NUVL	Nuvalent, Inc.	5,324,433	$545,488,160
4	PCVX	Vaxcyte, Inc.	4,793,020	$278,522,392
5	EWTX	Edgewise Therapeutics, Inc.	7,365,038	$231,998,697
6	GMAB	Genmab A/S	7,967,836	$213,777,039
7	INSM	INSMED Inc	1,254,488	$205,133,877
8	TARS	Tarsus Pharmaceuticals, Inc.	2,562,154	$179,735,103

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$168,153,918	10,392,702	-31.4%	Shares	Sole	2026-05-15
2026-01-07	$78,372,521	15,159,095	+7.1%	Shares	Sole	2026-01-14
2025-12-31	$52,671,833	14,159,095	+4.4%	Shares	Sole	2026-02-17
2025-09-30	$29,560,837	13,560,017	+13.9%	Shares	Sole	2025-11-14
2025-06-30	$15,122,121	11,907,182	+10.2%	Shares	Sole	2025-08-14
2025-03-31	$14,799,224	10,802,354	+0.5%	Shares	Sole	2025-05-15
2024-12-31	$26,988,408	10,752,354	+0.8%	Shares	Sole	2025-02-14
2024-09-30	$29,124,024	10,668,141	+47.1%	Shares	Sole	2024-11-14
2024-06-30	$17,110,000	7,250,000	—	Shares	Sole	2024-08-14
No filing history on record for this holder in this stock.